MerriKay Oleen-Burkey

Author

Health Outcomes Solutions (United States)

Also Known As

M Oleen-Burkey, M. A. Oleen-Burkey, M. Oleen-Burkey, M.A. Oleen-Burkey, MerriKay A. Oleen-Burkey, MerriKay Oleen-Burkey, Merrikay Oleen-Burkey, Merrikay OleenBurkey

Publications

1.1K

Citations

H-Index

Concepts

All Affiliations

Health Outcomes Solutions (United States)Teva Pharmaceuticals (United States)University of Maryland, Baltimore Multiple Sclerosis Foundation University of Kansas

About

MerriKay Oleen-Burkey is an author at Health Outcomes Solutions (United States) specializing in medicine, multiple sclerosis, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	11	11	430
2	Public Health	2	2	35
3	Allergy	2	2	28
4	Allergy Medicine	1	1	12
5	Diabetes	1	1	63

MerriKay Oleen-Burkey

Publications

1.1K

Citations

H-Index

Page 1

	Year	Citations
Fatigue characteristics in multiple sclerosis: the North American Research Committee on Multiple Sclerosis (NARCOMS) survey Olympia Hadjimichael, Timothy Vollmer, MerriKay Oleen-Burkey Health and Quality of Life Outcomes	2008	233
Cost-effectiveness of Four Immunomodulatory Therapies for Relapsing-Remitting Multiple Sclerosis: A Markov Model Based on Long-term Clinical Data Christopher F. Bell, Stephanie Earnshaw, MerriKay Oleen-Burkey, Journal of Managed Care Pharmacy	2007	106
Medical chart validation of an algorithm for identifying multiple sclerosis relapse in healthcare claims Benjamin Chastek, MerriKay Oleen-Burkey, Maria Lopez-Bresnahan Journal of Medical Economics	2010	100
The Impact of Comorbid Depression on Adherence to Therapy for Multiple Sclerosis Marcy Tarrants, MerriKay Oleen-Burkey, Jane Castelli‐Haley, Multiple Sclerosis International Psychological Co-morbiditiesComorbid DepressionPsychiatric DiseasePsychiatryComorbid Psychiatric Disorder	2011	82
Burden of a Multiple Sclerosis Relapse MerriKay Oleen-Burkey, Jane Castelli‐Haley, Maureen J. Lage, Patient Multiple Sclerosis RelapseDisease ProgressionNeurological DisorderMedicineNeurology	2012	79
Clinical and Economic Impact of Glatiramer Acetate Versus Beta Interferon Therapy Among Patients With Multiple Sclerosis in a Managed Care Population Daniel A. Ollendorf, Evguenia Jilinskaia, MerriKay Oleen-Burkey Journal of Managed Care Pharmacy	2002	76
Cost and resource utilization for prevention and treatment of foot lesions in a diabetic foot clinic in Belgium K. Van Acker, MerriKay Oleen-Burkey, Laure de Decker, Diabetes Research and Clinical Practice Resource UtilizationHealth PolicyDiabetic Foot ClinicDiabetesLower Extremity Wound	2000	63
Therapy Optimization in Multiple Sclerosis: A cohort study of therapy adherence and risk of relapse Bruce A. Cohen, Patricia K. Coyle, Thomas Leist, Multiple Sclerosis and Related Disorders Disease ProgressionPsychiatryTreatment And PreventionClinical TrialsTreatment Option	2014	51
Pregnancy Complications Associated With BacterialVaginosis and Their Estimated Costs MerriKay Oleen-Burkey, Sharon L. Hillier Infectious Diseases in Obstetrics and Gynecology	1995	48
The relationship between alternative medication possession ratio thresholds and outcomes: evidence from the use of glatiramer acetate MerriKay Oleen-Burkey, Avi Dor, Jane Castelli‐Haley, Journal of Medical Economics	2011	40

Page 1